Form 4: Inotiv Inc. Executive Acquires Stock Options

John Gregory Beattie, Chief Operating Officer of Inotiv, Inc., was granted stock options to purchase 6,500 shares of common stock.

Summary

• John Gregory Beattie, the Chief Operating Officer of Inotiv, Inc., was granted stock options on February 21, 2025.
• The options allow him to purchase 6,500 shares of Inotiv's common stock at an exercise price of $4.205 per share.
• The stock options vest over three years: 40% on February 21, 2026, 30% on February 21, 2027, and 30% on February 21, 2028, contingent upon continued employment.
• The options expire on February 21, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the COO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the COO.

Industry Context

Stock options are a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Charles River Laboratories and Envigo (now part of Inotiv) also utilize stock options as part of their compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the COO to improve company performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates